Company Overview and News
The acreage currently produces around 160 barrels of oil per day. AusTex will be the 50% owner and operator of the new joint venture and owns the assets in conjunction with a local Oklahoma-based private family company. AusTex’s share of the purchase price is US$3.25 million. The Drumright Dome (on which most of these wells sit) has been a prolific producer since the early 1900s, and these wells were generally drilled between the 1960s and 1980s.
What's more important: the size of the acreage or the amount of oil and gas gushing from it? Josh Young, founder of Young Capital Management, sees investors shifting their attention to the latter category. However, Young is more focused on the risk an investment poses compared to its potential reward. In this Energy Report interview, Young discusses which stocks have him particularly excited and why he sees interesting times ahead for oil - and the small caps that produce it.
Austex Oil (OTC:ATXDF) announced promising vertical Mississippian well results in Northwestern Kansas on August 13th. One well, targeting the Mississippian, tested at 100 barrels of oil per day, and the other, targeting the Arbuckle, tested at 16 barrels of oil per day (this may not sound great, but the company estimates a 100%+ IRR for this 16 bopd well, due to the low cost of drilling and completion).
There are three pure-play, small cap, publicly traded Mississippi Lime-focused companies of note: Osage Exploration (OEDV.OB), AusTex Oil (OTCQX:ATXDY) and Red Fork Energy (OTCPK:RDFEY). All three have their main acreage positions located just east of the Nemaha uplift, a structural feature which seems to indicate substantially better and more oily well results on its eastern side. Osage trades on the bulletin boards and the other two trade on the Australian stock market but are also listed on the OTCQX exchange.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...